Achieve Life Sciences (ACHV) Cash from Investing Activities (2010 - 2026)
Achieve Life Sciences (ACHV) recorded quarterly Cash from Investing Activities of $14.3 million in Q1 2026, up 1913.54% on a QoQ basis from $709000.0 in Q4 2025, and up 25.75% year-over-year from $11.4 million in Q1 2025.
Achieve Life Sciences (ACHV) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Achieve Life Sciences has disclosed Cash from Investing Activities across 15 years of filings, most recently posting $14.3 million for Q1 2026.
- Quarterly Cash from Investing Activities rose 25.75% year-over-year to $14.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.0 million (down 75.14% YoY) and the FY2025 annual result came in at $6.1 million, up 128.32% from the prior year.
- Cash from Investing Activities rose to $14.3 million in Q1 2026, from $709000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $14.3 million in Q1 2026 and troughed at -$12.7 million in Q3 2025.
- A 4-year average of $5.7 million and a median of $9.0 million in 2025 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2024 — Cash from Investing Activities jumped 195383.33% — and 2025, when it sank 195.35%.
- Tracing ACHV's Cash from Investing Activities over 4 years: stood at -$6000.0 in 2023, then soared by 195383.33% to $11.7 million in 2024, then tumbled by 93.95% to $709000.0 in 2025, then surged by 1913.54% to $14.3 million in 2026.
- Business Quant data shows ACHV's Cash from Investing Activities at $14.3 million in Q1 2026, $709000.0 in Q4 2025, and -$12.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 579,519.10 |
| 10 | Achieve Life Sciences | 93.71 Mn | 63.22 Mn | - | 14.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.28 Mn |
| Mar 31, 2026 | 14.28 Mn |
| Dec 31, 2025 | 709,000.00 |
| Dec 31, 2025 | 709,000.00 |
| Sep 30, 2025 | -12.65 Mn |
| Sep 30, 2025 | -12.65 Mn |
| Jun 30, 2025 | 6.70 Mn |
| Jun 30, 2025 | 6.70 Mn |
| Mar 31, 2025 | 11.35 Mn |
| Mar 31, 2025 | 11.35 Mn |
| Dec 31, 2024 | 11.72 Mn |
| Dec 31, 2024 | 11.72 Mn |
| Sep 30, 2024 | 13.27 Mn |
| Sep 30, 2024 | 13.27 Mn |
| Dec 31, 2023 | -6,000.00 |
| Dec 31, 2023 | -6,000.00 |
| Sep 30, 2020 | -3,000.00 |
| Sep 30, 2020 | -3,000.00 |
| Jun 30, 2020 | -12,000.00 |
| Jun 30, 2020 | -12,000.00 |